What Is Liraglutide Approved For? Label Indications, Per the Research

The short answer

Liraglutide is a prescription medicine and an acylated glucagon-like peptide-1 (GLP-1) receptor agonist. It holds marketing authorisation from the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and other national regulators under two distinct product programmes with two distinct labels: one indicated for glycaemic control in type 2 diabetes mellitus, and a higher-strength product indicated for chronic weight management. Each label defines its own eligible population, and the two are not interchangeable in regulatory terms.

This page describes what appears on those labels, when the relevant approvals were granted, and what the pivotal and comparative literature reported. It separates approved indications from uses that remain off-label or investigational. This page is for educational purposes only and is not medical advice; consult a licensed physician or pharmacist about whether any medicine is appropriate for an individual situation.

Approved indications at a glance

Label wording, eligibility criteria and warnings differ between jurisdictions and are revised over time. The authoritative text is the current prescribing information or summary of product characteristics published by the relevant regulator.

Where liraglutide came from

A review of the discovery and development of liraglutide and semaglutide described how native GLP-1 is degraded within minutes, and how attaching a fatty-acid side chain to a GLP-1 analogue promoted reversible albumin binding and extended the circulating half-life enough to support once-daily administration (PMID 31031702). The same review traced how that acylation strategy was carried forward into later analogues (PMID 31031702). A medicinal-chemistry paper describing the discovery of the once-weekly analogue semaglutide reported that further structural modification of the peptide backbone and the albumin-binding side chain produced a compound with a substantially longer duration of action (PMID 26308095).

Indication 1: type 2 diabetes

The first approved indication was glycaemic control in adults with type 2 diabetes as an adjunct to diet and exercise. A state-of-the-art review of GLP-1 receptor agonists in type 2 diabetes described this drug class as lowering glycated haemoglobin through glucose-dependent stimulation of insulin secretion and suppression of glucagon, with weight reduction and a low intrinsic risk of hypoglycaemia reported as class characteristics (PMID 33068776). That review also summarised cardiovascular outcome programmes across the class and noted that several agents demonstrated cardiovascular benefit in trials enrolling patients at elevated risk (PMID 33068776).

Cardiovascular risk reduction

The US label for the diabetes product was later expanded to include reduction of the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. This is a population-restricted indication tied to the trial population that supported it; the published class review situated such indications within the broader cardiovascular outcome evidence for GLP-1 receptor agonists (PMID 33068776). It is not a general cardiovascular indication for people without diabetes.

Paediatric type 2 diabetes

In 2019 the US diabetes label was extended to children aged 10 years and older with type 2 diabetes, following a dedicated paediatric trial programme. Eligibility criteria within that label are narrower than for adults and are set out in the prescribing information.

Indication 2: chronic weight management

A separate, higher-strength liraglutide product was approved in December 2014 in the United States and in 2015 in the European Union for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity, in adults meeting defined body-mass-index thresholds with or without weight-related comorbidities. A Lancet seminar on the management of obesity described pharmacotherapy as one component of a broader management framework that also includes dietary change, physical activity, behavioural support and, for selected patients, surgery (PMID 26868660).

A 2024 review of weight-loss pharmacotherapy placed liraglutide among the approved anti-obesity agents and described the shift in the field toward incretin-based medicines, noting differences in average weight change across agents reported in their respective trial programmes (PMID 39277293). A later overview of obesity management pharmacotherapy likewise catalogued the approved agents and emphasised that pharmacological treatment was studied as an adjunct to lifestyle intervention rather than a replacement for it (PMID 42101582).

Adolescents

In December 2020 the US weight-management label was extended to adolescents aged 12 to 17 years who met specified weight and body-mass-index criteria. A review of GLP-1 receptor agonists and GIP/GLP-1 co-agonists in adolescents and older adults summarised the evidence base in these age groups and reported that the trial data in adolescents were more limited than in adults, with gastrointestinal tolerability a recurring theme (PMID 40716192).

Younger children

A randomised trial published in The New England Journal of Medicine studied liraglutide in children aged 6 to under 12 years with obesity and reported a greater reduction in body-mass index with liraglutide than with placebo over the treatment period, alongside more frequent gastrointestinal adverse events in the liraglutide group (PMID 39258838). Whether that trial has translated into label coverage for this age group in a given country depends on the regulator and on the date of the labelling in question; the current prescribing information published by the relevant agency is the reliable source.

What comparative trials reported

The STEP 8 randomised clinical trial compared weekly subcutaneous semaglutide 2.4 mg with daily subcutaneous liraglutide 3.0 mg in adults with overweight or obesity without diabetes and reported a mean body-weight change of −15.8% with semaglutide versus −6.4% with liraglutide at week 68 (PMID 35015037). Researchers in that trial also reported that gastrointestinal adverse events were the most commonly observed events in both treatment groups (PMID 35015037). A head-to-head result of this kind describes relative average performance in one enrolled population; it does not alter what either medicine is approved for.

Adverse Events: What Studies Report

A review written for emergency clinicians reported that GLP-1 receptor agonists are commonly associated with nausea, vomiting, diarrhoea and other gastrointestinal effects, that delayed gastric emptying has implications relevant to procedural sedation, and that pancreatitis and gallbladder-related events have been described, with hypoglycaemia risk rising mainly when these agents are combined with insulin or insulin secretagogues (PMID 38241775). The state-of-the-art class review similarly described gastrointestinal intolerance as the most frequent reason for discontinuation across the GLP-1 receptor agonist class (PMID 33068776). In the paediatric trial in children aged 6 to under 12, researchers reported gastrointestinal adverse events more often with liraglutide than with placebo (PMID 39258838).

United States labelling for liraglutide products carries a boxed warning concerning thyroid C-cell tumours and sets out contraindications relating to personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2. The full warnings, contraindications and precautions section of the current prescribing information is the complete source for this material.

Uses that are not approved indications

Several lines of research describe liraglutide or the wider GLP-1 receptor agonist class in contexts that fall outside any approved label. These are investigational or off-label and are not presented here as approved uses.

• Anti-inflammatory and immunological effects. A pharmacological review summarised preclinical and clinical findings suggesting that GLP-1 receptor agonists modulate inflammatory and immune pathways across several tissue types, while describing the clinical significance of those signals as not yet established (PMID 35738455).
• Mechanistic work on brain access. A Cell Metabolism study reported that hypothalamic tanycytes controlled the uptake of liraglutide into the brain in mice and that this transport route influenced the drug's anti-obesity actions in that model (PMID 35716660). Findings in rodents describe biology, not clinical indications.
• Comparative and sequencing questions in obesity care. Reviews of weight-loss pharmacotherapy discussed how approved agents compare and where combination or sequential strategies have been examined, while noting that the evidence base continues to develop (PMID 39277293, PMID 42101582).

How to read an approval question accurately

1. Identify the product, not just the molecule. Liraglutide is marketed under separate labels for diabetes and for weight management, each with its own indication statement.
2. Check the jurisdiction. FDA and EMA indications and age ranges are similar in outline but not identical in detail.
3. Check the date. Labels are amended; paediatric and cardiovascular expansions were added years after initial approval.
4. Separate trial findings from label text. A published trial result, such as the comparative weight outcomes reported in STEP 8 (PMID 35015037), informs regulators but is not itself an indication.

Questions about eligibility, suitability, monitoring or alternatives are clinical questions and belong with a prescribing clinician who can review an individual's history. For background on the molecule itself, see the PeptideU liraglutide overview.

References

• Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial (JAMA, 2022)
• GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art (Molecular Metabolism, 2021)
• Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide (Journal of Medicinal Chemistry, 2015)
• The Discovery and Development of Liraglutide and Semaglutide (Frontiers in Endocrinology, 2019)
• Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial (The New England Journal of Medicine, 2025)
• Management of obesity (Lancet, 2016)
• Weight Loss Pharmacotherapy: Current and Future Therapies (Gastrointestinal Endoscopy Clinics of North America, 2024)
• GLP-1 agonists: A review for emergency clinicians (The American Journal of Emergency Medicine, 2024)
• The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists (Pharmacological Research, 2022)
• GLP-1 receptor agonists and GIP/GLP-1 co-agonists in the treatment of obesity in adolescents and the elderly (Medicina Clinica, 2025)
• Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions (Cell Metabolism, 2022)
• Obesity Management: Pharmacotherapy (FP Essentials, 2026)